Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)
J J Vehreschild, A Böhme, O A Cornely, C Kahl, M Karthaus, K-A Kreuzer, G Maschmeyer, S Mousset, V Ossendorf, O Penack, M J G T Vehreschild, J Bohlius, J J Vehreschild, A Böhme, O A Cornely, C Kahl, M Karthaus, K-A Kreuzer, G Maschmeyer, S Mousset, V Ossendorf, O Penack, M J G T Vehreschild, J Bohlius
Abstract
Background: Current evidence on myelopoietic growth factors is difficult to overview for the practicing haematologist/oncologist. International guidelines are sometimes conflicting, exclude certain patient groups, or cannot directly be applied to the German health system. This guideline by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO) gives evidence-based recommendations for the use of G-CSF, pegylated G-CSF, and biosimilars to prevent infectious complications in cancer patients undergoing chemotherapy, including those with haematological malignancies.
Methods: We systematically searched and evaluated current evidence. An expert panel discussed the results and recommendations. We then compared our recommendations to current international guidelines.
Results: We summarised the data from eligible studies in evidence tables, developed recommendations for different entities and risk groups.
Conclusion: Comprehensive literature search and expert panel consensus confirmed many key recommendations given by international guidelines. Evidence for growth factors during acute myeloid leukaemia induction chemotherapy and pegfilgrastim use in haematological malignancies was rated lower compared with other guidelines.
Keywords: G-CSF; cancer; evidence-based guideline; febrile neutropenia; infection; supportive care.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Source: PubMed